when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

ASTELLAS · news · pharmadog

← back to ASTELLAS

News mentioning ASTELLAS

61 stories

19hVistagen cuts workforce for second time in 2026biospace

5dLilly shuffles business structure; Novartis writes off part of Avidity dealbiopharma dive

5dAstellas bets up to $1.34B for option to advance Audax immuno-oncology assetbiospace

5dAstellas buys option on preclinical IL-12 cancer drug from Audax Biosciencesendpoints

6dAstellas makes $1.3B bet on Audax’s preclinical push to reverse decades of IL-12 woesfiercebiotech

6d‘The patient need is enormous’: Syntax programs stem cells into pancreatic beta cells in 4 daysfiercebiotech

11dESMO: Takeda’s $1.2B bet on Innovent ‘absolutely’ pays off with details of ADC’s phase 3 winfiercebiotech

13dAstellas links up with AI Proteins in $400M computational drug discovery dealfiercebiotech

13dExclusive: Astellas partners with Boston ‘miniproteins’ startupendpoints

19dGilead snags equity stake in Vir with up to $1.87B deal for three T cell engagersbiospace

19dJ&J earnings set ‘negative tone’; Shkreli vs. the FTCbiopharma dive

20dFrom Scientific Hypothesis to Clinical Practice: The Next Chapter for CLDN18.2fiercebiotech

20dVir CEO sees ‘opportunity to do more deals’ after striking $1.9B Gilead pact for dual-masked TCEsfiercebiotech

21dRevMed's Rasonque gets a subtype data asterisk, but analysts remain bullishbiospace

28dKairos seizes moment to push prostate cancer prospect into earlier settingfiercebiotech

28d2 Massachusetts biotechs call it quitsbiospace

Sep 23, 26‘It’s certainly not easy’: How are Boston biotechs coping with a shallower pool of seed funding?fiercebiotech

Sep 22, 26Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 winfiercebiotech

Sep 17, 26Cellares and Ori Biotech’s new cell therapy manufacturing contractsendpoints

Sep 16, 26Sling banks $123M for an experimental thyroid eye disease pillbiopharma dive

Sep 16, 26Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye diseaseendpoints

Sep 15, 26Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trialfiercebiotech

Sep 10, 26Drugmakers cherry pick launch regions as MFN creates 'policy environment like an earthquake'biospace

Sep 2, 26Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN dealsbiospace

Sep 1, 26Mid-cap biotechs join Trump’s latest round of drug pricing dealsbiopharma dive

Sep 1, 26STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and morestat

Sep 1, 269 midsize drugmakers climb aboard Trump’s MFN trainbiospace

Aug 31, 26STAT+: Trump strikes nine more deals with drugmakers to lower pricesstat

Aug 25, 26Will a ‘reset’ reignite investment in women’s health startups?biopharma dive

Aug 13, 26PTC takes a chance on Sangamo’s Fabry disease gene therapybiopharma dive

← prevpage 1 of 3next →